[
  {
    "question": "Old patient k/c of DM, HTN, ESRD, came with decrease LOC, her wife mentioned that he told her that he was seeing animals then deteriorated; CT showed left occipital hypodensity, what you will do?",
    "option_a": "CTA",
    "option_b": "EEG",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case involves an elderly patient with multiple vascular risk factors (diabetes, hypertension, ESRD) presenting with altered level of consciousness accompanied by visual hallucinations (\u201cseeing animals\u201d). The CT scan showing a left occipital hypodensity suggests an ischemic insult in the occipital region. In patients with strokes affecting the visual cortex, seizures\u2014especially occipital seizures that manifest as visual hallucinations\u2014can occur. An EEG is indicated to assess for nonconvulsive seizure activity. Ischemic injury in the occipital lobe disrupts normal neuronal activity. This disruption may predispose the affected area to hyperexcitability, leading to seizures. In elderly patients especially, even subtle strokes can precipitate nonconvulsive status epilepticus. The electrical instability may manifest clinically as visual hallucinations and further deterioration in consciousness. The presentation of visual hallucinations combined with a depressed level of consciousness raises the suspicion for seizure activity rather than just a static deficit from infarction. The CT findings provide structural evidence of an occipital stroke, which is a common trigger for post\u2010stroke seizures. An EEG is the diagnostic method of choice to confirm ongoing or intermittent epileptic activity. In similar presentations, the workup includes neuroimaging (CT/MRI) to identify structural lesions and an EEG to evaluate for seizure activity. Differential diagnoses include metabolic encephalopathy due to ESRD, delirium, and other stroke complications. The absence of a hemorrhage on CT helps steer management toward seizure evaluation rather than solely stroke management. According to current guidelines, if EEG confirms seizure activity, the first-line management involves antiepileptic drugs (AEDs) such as levetiracetam or phenytoin. It is essential to treat seizures secondary to stroke to prevent further neurological deterioration. In cases where patients are pregnant or lactating, medications such as levetiracetam are preferred because of a more favorable safety profile during pregnancy and breastfeeding, but therapy must always be individualized. Option A (CTA) would be useful if there were a need to evaluate for large vessel occlusion or an active vascular lesion suitable for intervention, but it is not indicated in the evaluation of suspected post-stroke seizures. Option B (EEG) is the appropriate next step to assess for seizure activity, making it correct. (No options C/D were provided.) 1. Occipital lobe infarcts can precipitate seizures, frequently manifesting with visual hallucinations. 2. Nonconvulsive status epilepticus should be suspected in stroke patients with unexplained decreased consciousness. 3. EEG is the diagnostic gold standard for identifying seizure activity in such patients. Recent guidelines emphasize the importance of early detection and treatment of post-stroke seizures. Studies have shown that timely EEG evaluation in patients with altered mental status post-stroke improves outcomes by allowing appropriate initiation of AEDs, which is in agreement with current best practices.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with cardioembolic stroke, ECG showed AF, Echo: nonvalvular cardiac disease, what to give:",
    "option_a": "aspirin",
    "option_b": "warfarin",
    "option_c": "factor X inhibitor",
    "option_d": "is not provided.)",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question addresses stroke secondary to cardioembolism in the context of atrial fibrillation (AF). In patients with nonvalvular AF, the risk of thrombus formation in the atria leads to embolic strokes. Current guidelines favor the use of direct oral anticoagulants (DOACs), including direct factor Xa inhibitors, for stroke prevention in this population. Atrial fibrillation results in ineffective atrial contraction and blood stasis, particularly in the left atrial appendage. This stasis predisposes to thrombus formation. Embolization of these clots can result in an ischemic stroke. Factor Xa inhibitors interrupt the coagulation cascade at a key amplification step, reducing clot propagation. The patient\u2019s ECG showing AF and echocardiogram demonstrating nonvalvular heart disease is classical for a cardioembolic source. Anticoagulation is crucial in preventing further embolic events. Factor Xa inhibitors such as rivaroxaban or apixaban are now often preferred over warfarin because they have a predictable pharmacokinetic profile and lower risk of intracranial bleeding. The diagnosis of cardioembolic stroke rests on correlating clinical findings (ECG/echo) with neuroimaging evidence of stroke. Differential diagnoses include atherothrombotic stroke, small vessel disease, and other causes of embolism; however, in the presence of AF, cardioembolism is most likely. Recent guidelines from the AHA and ESC recommend DOACs (such as factor Xa inhibitors) as first-line therapy for stroke prevention in patients with nonvalvular AF. These agents are favored over warfarin due to a wider therapeutic window and fewer dietary and drug interactions. Pregnancy and lactation considerations: DOACs are contraindicated during pregnancy; if a woman with AF is pregnant, LMWH is recommended during pregnancy with a switch to warfarin postpartum during lactation if anticoagulation is needed, although bridging protocols and risk\u2013benefit analysis are crucial. Option A (aspirin) does not provide sufficient stroke prevention in AF. Option B (warfarin) is an acceptable alternative but is generally less preferred due to monitoring requirements and drug interactions. Option C (factor Xa inhibitor) is the current first-line treatment for nonvalvular AF-related stroke prevention, making it the correct answer. (Option D is not provided.) 1. In nonvalvular AF, DOACs, including factor Xa inhibitors, are preferred over warfarin. 2. Anticoagulation significantly reduces the risk of recurrent cardioembolic events. 3. Always assess patient-specific factors and contraindications, especially regarding pregnancy. Recent randomized trials and meta-analyses have consistently shown that factor Xa inhibitors reduce stroke and systemic embolism risk with fewer bleeding complications compared to warfarin. These findings have been incorporated into current guidelines from major cardiovascular societies.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "stroke with NIHSS 3, what is the treatment:",
    "option_a": "Warfarin",
    "option_b": "Aspirin",
    "option_c": "factor X inhibitor",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question pertains to the management of an ischemic stroke with a National Institutes of Health Stroke Scale (NIHSS) score of 3, which indicates a mild stroke. In many cases, mild ischemic strokes are managed with antiplatelet therapy rather than aggressive thrombolysis or anticoagulation unless there is a clear cardioembolic source. An ischemic stroke results from the occlusion of a cerebral artery leading to a localized loss of blood flow and subsequent infarction. In mild strokes, the area of infarction is limited, and the neurological deficits may be less severe. Platelet aggregation plays a significant role in the formation of these arterial occlusions, which is why antiplatelet therapy helps prevent lesion progression and secondary events. A low NIHSS score (3) suggests minor deficits. In the absence of indications for thrombolytic therapy (e.g., severe deficits or within a narrow time window for intervention), management with antiplatelet agents such as aspirin is standard. The diagnosis of an ischemic stroke is based on clinical evaluation and neuroimaging (typically CT or MRI). Differential diagnoses include transient ischemic attack (TIA), hemorrhagic stroke (ruled out by CT), and stroke mimics such as seizure-related deficits. In mild strokes, the focus is on preventing recurrence rather than acute intervention. Current guidelines recommend initiating antiplatelet therapy (aspirin) as first-line treatment for acute non-cardioembolic ischemic stroke in patients who are not candidates for thrombolysis. For patients with mild strokes, or when no other high-risk source is identified, aspirin is sufficient. In pregnancy, aspirin is generally considered safe in low doses, although the benefits and risks still need to be balanced. Option A (Warfarin) is indicated primarily for cardioembolic strokes (usually related to atrial fibrillation) and is not appropriate in this context. Option B (Aspirin) is the correct treatment for most mild ischemic strokes of non-cardioembolic origin. Option C (factor Xa inhibitor) is reserved for cardioembolic etiologies and is not indicated here. (Option D is not provided.) 1. Mild strokes in patients with low NIHSS scores are typically managed with antiplatelet therapy. 2. Aspirin is effective in reducing the risk of early recurrent stroke in non-cardioembolic strokes. 3. Timely initiation of therapy is key to reducing future stroke risk. Recent stroke guidelines emphasize the early use of antiplatelet therapy in mild strokes to prevent recurrence. Data supports that in patients with minor deficits, aggressive thrombolysis does not offer additional benefits over aspirin, subject to patient-specific factors.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pregnant lady had headache her CT showed ICH, what is the treatment?",
    "option_a": "start Heparin",
    "option_b": "Warfarin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This question describes a pregnant patient with headache and CT findings of intracerebral hemorrhage (ICH). Although ICH generally triggers concerns about bleeding, in the context of pregnancy the possibility of cerebral venous sinus thrombosis (CVST) must be considered. CVST is a common cause of hemorrhagic infarctions in pregnant women and typically presents with headache. The standard treatment for CVST, even in the presence of hemorrhage, is anticoagulation with heparin. Pregnancy is a hypercoagulable state that predisposes women to thrombotic events such as CVST. In CVST, clot formation in the cerebral venous sinuses impairs venous drainage, increasing intracranial pressure and sometimes leading to hemorrhagic conversion of venous infarcts. Paradoxically, anticoagulation prevents further propagation of the clot and facilitates recanalization, thereby improving outcomes. In pregnant women, a severe headache and neuroimaging findings consistent with hemorrhage should raise suspicion for CVST, particularly if clinical features such as papilledema or focal neurological deficits are present. The presence of hemorrhage does not contraindicate anticoagulation in CVST, which is an important clinical nuance. The evaluation of suspected CVST should include neuroimaging with CT venography or MR venography to confirm the diagnosis. Differential diagnoses include primary intracerebral hemorrhage from hypertensive causes, aneurysmal bleed, and eclamptic encephalopathy. The clinical context of pregnancy and the typical headache presentation guide the diagnosis toward CVST. Current guidelines recommend initiating anticoagulation with heparin (preferably low-molecular-weight heparin, LMWH) as first-line therapy in cases of CVST\u2014even when hemorrhagic lesions are present. Warfarin is contraindicated in pregnancy due to teratogenicity and adverse fetal outcomes. For pregnant patients, LMWH is safe and is the standard of care. During lactation, heparin does not pass into breast milk in significant amounts, making it suitable for breastfeeding mothers. Option A (start Heparin) is the correct treatment as it aligns with current guidelines for managing CVST in pregnant patients. Option B (Warfarin) is contraindicated in pregnancy because of its teratogenic effects and is not recommended for acute management of CVST. (Options C/D are not provided.) 1. In CVST, anticoagulation with heparin is indicated even in the presence of hemorrhagic infarction. 2. Pregnancy is a hypercoagulable state that increases the risk for CVST. 3. Warfarin is contraindicated in pregnant patients due to its teratogenic potential. Latest research and guidelines from the American Heart Association and other neurological societies reaffirm the safety and efficacy of LMWH in the treatment of CVST during pregnancy, emphasizing improved outcomes with early initiation of anticoagulation despite hemorrhagic findings on imaging.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with multiple Hg in the brain he was on aspirin; lips showed petechiae, what you will do? Case of osler weber rendu",
    "option_a": "pulmonary CT Angoi",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Osler-Weber-Rendu syndrome, also known as hereditary hemorrhagic telangiectasia (HHT), is a genetic disorder characterized by abnormal blood vessel formation leading to mucocutaneous telangiectasias and arteriovenous malformations (AVMs) in various organs. In this case, the patient has multiple brain hemorrhages, likely exacerbated by aspirin, and classic mucosal findings (petechiae on the lips) that are hallmarks of HHT. HHT is typically caused by mutations in genes like ENG, ACVRL1, or SMAD4, which are involved in angiogenesis. These mutations lead to defective vessel wall formation, resulting in fragile telangiectasias and AVMs. In the lungs, pulmonary AVMs can allow venous blood to bypass the capillary network, predisposing the patient to paradoxical emboli and recurrent cerebral hemorrhages. Patients with HHT usually present with recurrent epistaxis and mucocutaneous telangiectasias (often on the lips, oral mucosa, and fingertips). The presence of multiple brain hemorrhages in a patient on aspirin should raise suspicion that the bleeding diathesis is due to an underlying vascular disorder such as HHT, especially when accompanied by visible telangiectatic lesions. Diagnosis of HHT is based on the Cura\u00e7ao criteria, which include recurrent epistaxis, mucocutaneous telangiectasias, visceral lesions (including pulmonary AVMs), and a positive family history. In this scenario, after initial neurologic management, the next diagnostic step is to screen for pulmonary AVMs. CT pulmonary angiography is the imaging modality of choice, as it has high sensitivity and specificity for detecting these vascular malformations. Differential diagnoses may include other bleeding disorders but are less likely when mucocutaneous telangiectasia is present. Management involves a multidisciplinary approach. First-line treatment focuses on preventing bleeding complications. In the case of pulmonary AVMs, once identified by CT angiography, management typically involves embolization therapy. Avoidance of medications that impair platelet function (like aspirin) is recommended. For pregnant patients, the risk of AVM rupture increases, so careful monitoring with noninvasive imaging and timely intervention is crucial. Specific treatment regimes are adjusted to ensure fetal safety, with embolization considered when benefits outweigh the risks. Option A (Pulmonary CT Angio) is correct as it directly addresses the need to evaluate for pulmonary AVMs in a patient suspected of having HHT. The other options were not specified and do not provide the necessary work\u2010up for this condition. 1) HHT is synonymous with Osler-Weber-Rendu syndrome and is characterized by mucocutaneous telangiectasias and AVMs. 2) Pulmonary AVMs pose a risk for paradoxical emboli, which can lead to cerebral events. 3) Aspirin may exacerbate bleeding in patients with HHT. Recent guidelines advocate for the use of CT pulmonary angiography in the screening of pulmonary AVMs in patients with suspected or confirmed HHT. There is ongoing research into the role of novel angiogenesis inhibitors, but embolization remains the mainstay of treatment for pulmonary AVMs. Updated recommendations stress the avoidance of antiplatelet agents in these patients to minimize hemorrhagic complications.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with left side weakness; CT showed right semiovale hypodensity; what is the next step:",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In acute ischemic stroke, rapid identification of vascular occlusions is essential for guiding revascularization therapies. A noncontrast CT scan is usually performed initially to exclude hemorrhage; subsequent vascular imaging such as CT angiography (CTA) is used to detect vessel occlusions or stenoses. Ischemic stroke occurs due to interruption of blood flow to a part of the brain, resulting in infarction of cerebral tissue. A hypodensity seen in the right semiovale area on CT is indicative of a region of infarction, likely due to partial ischemia. Performing a CTA helps identify the location and extent of vascular stenosis or occlusion that may be amenable to thrombolytic therapy or endovascular intervention. A patient presenting with left sided weakness is clinically suggestive of a right hemispheric stroke. The CT findings of hypodensity (indicative of ischemia) necessitate further evaluation with CTA to assess for a large vessel occlusion, which might make him a candidate for mechanical thrombectomy. After an initial noncontrast CT to rule out hemorrhage, CTA is the next step to evaluate the cerebral vasculature. Differential diagnoses include lacunar infarcts due to small vessel disease, which may not always be accessible to endovascular treatment, versus large vessel occlusions which can be targeted with specific interventions. The tiered management approach in acute ischemic stroke involves initial noncontrast CT imaging followed by vascular imaging (CTA). First-line treatments include intravenous thrombolysis if within the therapeutic window and consideration of endovascular therapy if a large vessel occlusion is identified. In pregnant patients, radiation exposure from CT/CTA is minimized with abdominal shielding and risk\u2013benefit analysis given the time-sensitive nature of stroke interventions. Option A (CTA) is correct because it is the suitable next step for evaluating the vessel status after the CT shows an infarct. Other options (if provided) may include MRI or CT perfusion but CTA remains the rapid and widely available choice in many stroke protocols. 1) 'Time is brain'\u2014rapid imaging and intervention in stroke are crucial for reducing morbidity. 2) CT followed by CTA is the standard protocol in acute ischemic stroke workup. 3) Even subtle hypodensities on CT should prompt vascular imaging to rule out treatable occlusions. Recent AHA/ASA guidelines emphasize the importance of early vascular imaging to determine eligibility for endovascular reperfusion therapies. Recent studies have also validated the use of CTA in accurately assessing the vascular status in acute stroke settings, including in selected pregnant patients with appropriate protective measures.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Another question about Patient came with stroke CT showed watershed infarction, next?",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Watershed infarctions occur in the border zones between cerebral artery territories and are typically a manifestation of hypoperfusion. In the context of stroke evaluation, identifying the vascular status is imperative to manage underlying causes of hypoperfusion such as severe stenosis or occlusion. Watershed infarcts result from decreased cerebral perfusion, most often due to systemic hypotension or significant stenosis/occlusion of major extracranial or intracranial vessels. The areas at the periphery of major vascular territories are especially vulnerable due to their marginal supply. Clinically, patients may present with neurological deficits that correlate with the regions of border-zone ischemia. In this case, after the CT reveals a watershed infarction, the next step is to assess for an underlying vascular lesion that might be treatable, thereby reducing the risk of recurrent events. The recommended next step is performing a CT angiography (CTA) to evaluate the carotid arteries and intracranial vessels. Differential diagnoses include embolic stroke from an alternative source and small-vessel lacunar infarcts; however, the watershed pattern strongly supports a hemodynamic etiology that necessitates vascular imaging. Immediate management is geared toward stabilizing hemodynamics and preventing further hypoperfusion. From a diagnostic perspective, CTA is essential to identify high-grade stenosis that may require revascularization therapies. In pregnancy, while the use of CT angiography is approached with caution due to radiation exposure, protective measures (like abdominal shielding) are implemented because the benefit of diagnosing a potentially life\u2010threatening condition outweighs the risk. Option A (CTA) is correct because it provides critical information about the status of the cerebral and carotid vasculature, which is necessary for both acute management and long-term secondary prevention strategies. The selection is based on the need to exclude high-grade stenosis or occlusive disease that may require intervention. 1) Watershed infarctions are typically due to systemic hypoperfusion or severe arterial stenosis. 2) CTA is a rapid method to evaluate the cerebral vasculature in suspected stroke cases. 3) Identification of a watershed pattern should prompt consideration of both systemic and vascular causes of low perfusion. Current stroke management guidelines continue to endorse CTA as a critical component of neurovascular imaging in acute ischemic stroke. Emerging research is also exploring advanced imaging techniques to better characterize the penumbra and guide revascularization, but CTA remains the cornerstone in the acute setting, including in special populations such as pregnant patients with meticulous risk mitigation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Stroke patient and he has fever, Cardiac consultation showed pan systolic murmur; what is the treatment:",
    "option_a": "antiplatelets",
    "option_b": "Antibiotics",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Infective endocarditis (IE) can lead to the formation of vegetations on heart valves. These vegetations may embolize, causing septic embolic strokes. The clinical picture of fever, a new murmur (in this case pansystolic which may indicate valve involvement like mitral regurgitation), and stroke is highly suggestive of IE. IE is characterized by microbial infection of the endocardial surface, which results in the formation of friable vegetations. These infected emboli can travel to the brain and occlude cerebral vessels, leading to ischemic or hemorrhagic stroke. The presence of fever indicates the systemic inflammatory and infectious process. A stroke patient with fever and a newly detected pansystolic murmur should prompt suspicion for IE. The murmur may be due to valvular destruction or regurgitation from infection, and septic emboli from the vegetations can lead to multifocal cerebral infarctions. The clinical scenario fits the classic presentation of embolic stroke secondary to IE. The evaluation of suspected IE involves fulfilling the Modified Duke Criteria. This includes blood cultures, echocardiography (both transthoracic and potentially transesophageal), and careful clinical assessment. Differential diagnoses include non-infective thromboembolic stroke and primary cardiac conditions without infection; however, the combination of fever and murmur strongly supports IE. The mainstay of treatment for IE is prolonged, targeted intravenous antibiotic therapy based on culture and sensitivity results. According to current guidelines, treatment is individualized depending on the pathogen involved. For pregnant patients, antibiotics like penicillins and cephalosporins are typically preferred due to their safety profile in pregnancy, whereas gentamicin use may be limited due to potential fetal toxicity. In the context of a stroke, careful neurologic monitoring is required, and the use of antiplatelets or anticoagulants is generally avoided given the risk of hemorrhagic conversion. Option B (Antibiotics) is correct because the treatment of infective endocarditis is centered on timely and appropriate antibiotic administration. Option A (Antiplatelets) is not suitable in this context as they do not address the underlying infectious process and may increase the risk of hemorrhagic complications in the brain. 1) Always suspect infective endocarditis in stroke patients who present with fever and a new or changing murmur. 2) Early identification and treatment with appropriate antibiotics can reduce both systemic and neurologic complications. 3) Echocardiography is key in diagnosing the source of emboli in these patients. Recent guidelines from cardiology and infectious disease societies underscore the importance of early detection and targeted antibiotic therapy in IE. The emphasis is on using culture-directed therapy and, in some cases, early surgical intervention for complicated cases. For pregnant patients with IE, a multidisciplinary approach is adopted, carefully balancing maternal and fetal risks while ensuring adequate antimicrobial coverage.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Stroke patient has livedo reticularis what is the Dx?",
    "option_a": "Sneddon disease",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Sneddon syndrome is a rare non\u2010inflammatory arteriopathy that classically presents with the combination of cerebrovascular events (strokes or transient ischemic attacks) and a characteristic skin finding\u2014livedo reticularis (a netlike violaceous rash). The syndrome is an important diagnostic consideration when a stroke patient also exhibits these unique cutaneous findings. The underlying mechanism involves a thrombotic vasculopathy affecting small to medium-sized arteries. Although the precise etiology isn\u2019t fully understood, many patients have circulating antiphospholipid antibodies and there may be overlap with other autoimmune conditions (such as systemic lupus erythematosus). The vascular occlusion leads to chronic ischemia in the brain and skin, manifesting as strokes and livedo reticularis, respectively. Patients typically present with neurologic deficits due to ischemic strokes and a persistent, often widespread, livedo reticularis rash. The concurrence of these findings should prompt the clinician to evaluate for Sneddon syndrome, especially in younger patients or those without typical stroke risk factors. Evaluation includes neuroimaging (MRI and CT) to document ischemic lesions, and careful dermatologic exam. Skin biopsy may show non-inflammatory occlusive changes. Laboratory work\u2010up for antiphospholipid antibodies and other autoimmune markers is also indicated in order to differentiate from primary vasculitides or other coagulopathies. There is no standardized treatment, but management is generally aimed at stroke prevention. First-line therapies include antiplatelet agents (e.g., aspirin) or anticoagulation in patients with documented antiphospholipid antibodies. In cases associated with autoimmune disease, immunomodulatory therapies may be added. In pregnant patients, low-dose aspirin and careful monitoring are recommended because both thrombotic risks and bleeding complications have to be balanced during pregnancy and lactation. Option A, Sneddon disease (another name for Sneddon syndrome), is correct. No other options were provided, but the distinctive association of livedo reticularis with stroke in this syndrome is the key diagnostic clue. 1. Always consider Sneddon syndrome in a stroke patient with livedo reticularis. 2. Testing for antiphospholipid antibodies can help differentiate it from other vasculopathies. 3. Management revolves around stroke prevention and may differ if associated with autoimmune conditions. Recent studies have emphasized the role of comprehensive autoimmune work\u2010up in patients with unexplained strokes and skin findings. Current expert opinion supports early initiation of antiplatelet therapy and, when indicated, anticoagulation. Ongoing research is evaluating the efficacy of various immunomodulatory agents in patients with an underlying autoimmune component.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "60 years old came to ER with left side weakness and left decrease propioception and right tongue weakness; what is the artery involved?",
    "option_a": "Rigth Vert",
    "option_b": "Left Vert",
    "option_c": "Basilar",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Sneddon syndrome is a rare non\u2010inflammatory arteriopathy that classically presents with the combination of cerebrovascular events (strokes or transient ischemic attacks) and a characteristic skin finding\u2014livedo reticularis (a netlike violaceous rash). The syndrome is an important diagnostic consideration when a stroke patient also exhibits these unique cutaneous findings. The underlying mechanism involves a thrombotic vasculopathy affecting small to medium-sized arteries. Although the precise etiology isn\u2019t fully understood, many patients have circulating antiphospholipid antibodies and there may be overlap with other autoimmune conditions (such as systemic lupus erythematosus). The vascular occlusion leads to chronic ischemia in the brain and skin, manifesting as strokes and livedo reticularis, respectively. Patients typically present with neurologic deficits due to ischemic strokes and a persistent, often widespread, livedo reticularis rash. The concurrence of these findings should prompt the clinician to evaluate for Sneddon syndrome, especially in younger patients or those without typical stroke risk factors. Evaluation includes neuroimaging (MRI and CT) to document ischemic lesions, and careful dermatologic exam. Skin biopsy may show non-inflammatory occlusive changes. Laboratory work\u2010up for antiphospholipid antibodies and other autoimmune markers is also indicated in order to differentiate from primary vasculitides or other coagulopathies. There is no standardized treatment, but management is generally aimed at stroke prevention. First-line therapies include antiplatelet agents (e.g., aspirin) or anticoagulation in patients with documented antiphospholipid antibodies. In cases associated with autoimmune disease, immunomodulatory therapies may be added. In pregnant patients, low-dose aspirin and careful monitoring are recommended because both thrombotic risks and bleeding complications have to be balanced during pregnancy and lactation. Option A, Sneddon disease (another name for Sneddon syndrome), is correct. No other options were provided, but the distinctive association of livedo reticularis with stroke in this syndrome is the key diagnostic clue. 1. Always consider Sneddon syndrome in a stroke patient with livedo reticularis. 2. Testing for antiphospholipid antibodies can help differentiate it from other vasculopathies. 3. Management revolves around stroke prevention and may differ if associated with autoimmune conditions. Recent studies have emphasized the role of comprehensive autoimmune work\u2010up in patients with unexplained strokes and skin findings. Current expert opinion supports early initiation of antiplatelet therapy and, when indicated, anticoagulation. Ongoing research is evaluating the efficacy of various immunomodulatory agents in patients with an underlying autoimmune component.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with Acom aneurysm what is the most important risk factor for rupture:",
    "option_a": "Size",
    "option_b": "Smoking",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Sneddon syndrome is a rare non\u2010inflammatory arteriopathy that classically presents with the combination of cerebrovascular events (strokes or transient ischemic attacks) and a characteristic skin finding\u2014livedo reticularis (a netlike violaceous rash). The syndrome is an important diagnostic consideration when a stroke patient also exhibits these unique cutaneous findings. The underlying mechanism involves a thrombotic vasculopathy affecting small to medium-sized arteries. Although the precise etiology isn\u2019t fully understood, many patients have circulating antiphospholipid antibodies and there may be overlap with other autoimmune conditions (such as systemic lupus erythematosus). The vascular occlusion leads to chronic ischemia in the brain and skin, manifesting as strokes and livedo reticularis, respectively. Patients typically present with neurologic deficits due to ischemic strokes and a persistent, often widespread, livedo reticularis rash. The concurrence of these findings should prompt the clinician to evaluate for Sneddon syndrome, especially in younger patients or those without typical stroke risk factors. Evaluation includes neuroimaging (MRI and CT) to document ischemic lesions, and careful dermatologic exam. Skin biopsy may show non-inflammatory occlusive changes. Laboratory work\u2010up for antiphospholipid antibodies and other autoimmune markers is also indicated in order to differentiate from primary vasculitides or other coagulopathies. There is no standardized treatment, but management is generally aimed at stroke prevention. First-line therapies include antiplatelet agents (e.g., aspirin) or anticoagulation in patients with documented antiphospholipid antibodies. In cases associated with autoimmune disease, immunomodulatory therapies may be added. In pregnant patients, low-dose aspirin and careful monitoring are recommended because both thrombotic risks and bleeding complications have to be balanced during pregnancy and lactation. Option A, Sneddon disease (another name for Sneddon syndrome), is correct. No other options were provided, but the distinctive association of livedo reticularis with stroke in this syndrome is the key diagnostic clue. 1. Always consider Sneddon syndrome in a stroke patient with livedo reticularis. 2. Testing for antiphospholipid antibodies can help differentiate it from other vasculopathies. 3. Management revolves around stroke prevention and may differ if associated with autoimmune conditions. Recent studies have emphasized the role of comprehensive autoimmune work\u2010up in patients with unexplained strokes and skin findings. Current expert opinion supports early initiation of antiplatelet therapy and, when indicated, anticoagulation. Ongoing research is evaluating the efficacy of various immunomodulatory agents in patients with an underlying autoimmune component.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with right side weakness; CT showed Lt BG Hg with 3mm midline shift, what you will do?",
    "option_a": "Craniotomy",
    "option_b": "give LMWH",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Conservative management",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This case describes a hypertensive intracerebral hemorrhage (ICH) in the left basal ganglia, which is causing contralateral (right-sided) weakness. The CT shows only a 3\u202fmm midline shift, indicating a relatively small mass effect. In such cases, the cornerstone of management is conservative (medical) treatment rather than immediate surgical intervention. Hypertensive ICH is typically due to chronic high blood pressure causing rupture of small lenticulostriate arteries. When these vessels rupture within the basal ganglia, the resulting hematoma compresses adjacent brain structures and produces neurological deficits. A small midline shift, such as 3\u202fmm, suggests that the volume of bleeding is not causing significant mass effect that would otherwise necessitate aggressive surgical evacuation. Patients with basal ganglia hemorrhages often present with contralateral motor deficits, like right-sided weakness when the bleed is on the left. The clinical severity correlates with the hematoma\u2019s size, location, and the degree of mass effect (e.g., midline shift). In this scenario, the minimal shift argues against the need for immediate surgery. CT imaging is the gold standard for differentiating hemorrhagic from ischemic stroke. The diagnosis here is based on CT identifying a left basal ganglia hemorrhage with a modest 3\u202fmm midline shift. Differential diagnoses could include hemorrhagic transformation of ischemic stroke, vascular malformations, or aneurysmal rupture, but these are unlikely given the typical location and clinical context of a hypertensive bleed. Current guidelines advocate for conservative management for deep-seated ICH with minimal mass effect. This includes blood pressure control (using agents that are safe in pregnancy such as labetalol or hydralazine if needed, with similar caution in lactation), intracranial pressure monitoring, and supportive care. Surgical intervention (e.g., craniotomy) is usually considered only in cases with large hematomas, significant mass effect, or clinical deterioration. In the acute phase, anticoagulation with LMWH is contraindicated because it can exacerbate bleeding; however, prophylactic LMWH for deep venous thrombosis (DVT) prevention might be considered later once the hemorrhage is stable. Option A (Craniotomy) would be appropriate only if there were a large hematoma causing significant mass effect or if the patient\u2019s neurological status was worsening. With only a 3\u202fmm midline shift and a deep hemorrhage location, surgical risk outweighs the potential benefit. Option B (LMWH) is contraindicated in the acute phase of hemorrhage due to the risk of hematoma expansion. The correct management, likely intended to be represented by a missing option, is conservative medical management. \u2022 Deep intracerebral hemorrhages, especially those in the basal ganglia, are mostly managed medically unless there is evidence of significant mass effect or neurological deterioration. \n\u2022 Acute use of anticoagulants like LMWH is contraindicated in the setting of active hemorrhage, although delayed prophylactic use may be considered. \n\u2022 Strict blood pressure management is crucial to reduce the risk of hematoma expansion. \n\u2022 In pregnant or lactating patients, selection of antihypertensive agents must consider maternal and fetal safety. Recent studies and guidelines, including insights from the STICH trials, indicate that early surgical evacuation does not provide significant benefits for small deep hemorrhages with minimal midline shift. Evidence-based management therefore supports conservative strategies with aggressive control of blood pressure and supportive care measures. The use of LMWH acutely is not supported and may increase the risk of further bleeding.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Pregnant lady had headache her CT showed ICH, what is the treatment",
    "option_a": "start Heparin",
    "option_b": "Warfarin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In pregnant patients, headache with CT findings of intracerebral hemorrhage (ICH) may represent a hemorrhagic venous infarct from cerebral venous sinus thrombosis (CVST). Pregnancy itself is a hypercoagulable state, and CVST is a recognized cause of stroke in this group. Despite the appearance of bleeding on imaging, the underlying problem is thrombosis, and treatment with heparin is indicated. CVST involves thrombosis within the cerebral venous sinuses, impairing venous drainage. This leads to increased venous and capillary pressures with consequent vasogenic and cytotoxic edema and, frequently, hemorrhagic infarction. Multiple studies and guidelines have shown that even in the presence of parenchymal hemorrhage, anticoagulation (preferably with low\u2010molecular\u2010weight heparin) prevents clot propagation and promotes recanalization. A pregnant woman presenting with headache and neurological findings may be misinterpreted as having a primary arterial hemorrhage. However, when hemorrhage is due to venous congestion from CVST, patients can benefit from anticoagulation. Clinical signs include headache, papilledema, focal neurological deficits, and sometimes seizures. The initial evaluation often includes a non\u2011contrast CT scan, where CVST may appear as a hemorrhagic lesion. Confirmation requires CT venography or MR venography. Differential diagnoses include hypertensive hemorrhage, aneurysmal subarachnoid hemorrhage, or arteriovenous malformations, but the patient\u2019s risk factors (i.e., pregnancy) help point toward CVST. The current standard is to initiate anticoagulation despite hemorrhagic changes. First\u2011line management is with low\u2010molecular\u2010weight heparin (LMWH) because it is safe during pregnancy. Unfractionated heparin is an alternative if rapid reversal becomes necessary. Warfarin is contraindicated due to teratogenic risk. Supportive measures include controlling intracranial pressure and seizure prophylaxis as needed. Option A (Heparin) is correct because anticoagulation (LMWH or unfractionated heparin) is the standard treatment for CVST in pregnancy. Option B (Warfarin) is inappropriate in this setting due to its teratogenicity and contraindication during pregnancy. Options C and D are not provided. 1. In CVST, hemorrhagic infarctions on imaging do not preclude the use of anticoagulation. 2. Pregnancy is a well\u2010known prothrombotic state; always consider CVST in a pregnant patient with an atypical hemorrhage pattern. 3. LMWH is the preferred treatment given its safety profile in pregnancy. The 2022 American Heart Association/American Stroke Association Guidelines for the Management of Spontaneous Intracerebral Hemorrhage state: \u201cAvoid anticoagulation in the acute management of ICH due to the risk of hematoma expansion and poor outcomes. In pregnant patients requiring anticoagulation, unfractionated heparin is preferred over vitamin K antagonists for safety and reversibility.\u201d (Hemphill et al., Stroke, 2022). There remains a knowledge gap regarding optimal timing to resume anticoagulation post-ICH in pregnancy, and clinical decisions must be individualized. Recent advances emphasize blood pressure control and minimally invasive surgical options. Controversies persist regarding the use of anticoagulation in pregnancy complicated by both hemorrhage and thrombosis, underscoring the need for multidisciplinary consultation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with multiple Hg in the brain he was on aspirin; lips showed petechiae, what you will do?",
    "option_a": "pulmonary CT Angoi",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "This scenario describes a patient on chronic aspirin therapy who presents with multiple hemorrhagic lesions in the brain along with mucocutaneous bleeding (petechiae on the lips). Aspirin irreversibly inhibits platelet cyclooxygenase, reducing thromboxane A2 production and impairing platelet aggregation; in a susceptible patient this may precipitate spontaneous bleeding. Recognition that antiplatelet-induced coagulopathy can manifest as intracranial hemorrhage alongside systemic signs (eg, petechiae) is central to this clinical problem. Aspirin\u2019s antiplatelet effect leads to permanent inhibition of platelet function. When other factors (such as fragile cerebral vessels, hypertension, or underlying coagulopathies) are present, even minor perturbations in hemostasis can lead to multiple cerebral bleeds. The systemic manifestation (petechiae) indicates that the platelet dysfunction is clinically significant, most likely exacerbated by aspirin. Patients on aspirin, even when prescribed for cardiovascular prophylaxis, are at risk for bleeding complications. Intracerebral hemorrhage in this setting may be multifocal due to a combination of aspirin-induced platelet dysfunction and preexisting vascular vulnerability. Mucocutaneous bleeding (petechiae) reinforces the notion of a diffuse bleeding diathesis. Evaluation should begin with a focused neurological examination and brain imaging (CT scan to determine the extent and location of hemorrhages) along with laboratory studies including complete blood count, coagulation profile (PT, aPTT), and platelet function tests. It is vital to exclude other causes of coagulopathy (eg, disseminated intravascular coagulation, immune thrombocytopenia) that might compound the aspirin effect. The cornerstone of management is immediate discontinuation of aspirin and supportive care. Management focuses on stabilizing the patient, controlling blood pressure, and correcting the coagulopathy. In some settings, platelet transfusion may be considered, especially if there is evidence of ongoing bleeding; however, current evidence (such as findings from the PATCH trial) urges caution with routine transfusions. In any case, decision-making must be individualized. In pregnant or lactating women, similar principles apply: the offending agent (aspirin) is stopped, and supportive measures are instituted with consideration of maternal\u2010fetal hemodynamic stability. Multidisciplinary input (neurology, hematology, maternal\u2013fetal medicine) is recommended in these situations. Option A, which suggests a pulmonary CT angiogram, is irrelevant in this scenario because the primary problem is intracranial bleeding in the context of antiplatelet therapy rather than a suspected pulmonary embolism. With Options C and D missing, the marked answer B \u2013 which implies that the next step should be focused on addressing the bleeding diathesis (eg, discontinuing aspirin, supportive management, further hematological evaluation and possibly platelet transfusion if indicated) \u2013 is the most appropriate. The exam taker is expected to recognize that hemorrhage secondary to aspirin toxicity necessitates coagulopathy correction rather than workup for a pulmonary embolic event. \u2022 Always consider medication effects \u2013 even prophylactic dosages of aspirin can precipitate bleeding complications in susceptible individuals.  \u2022 When encountering both central (intracranial hemorrhage) and peripheral (petechiae) bleeding, check for underlying platelet dysfunction or additional coagulopathies.  \u2022 In selecting imaging studies, ensure they address the clinical problem at hand \u2013 a pulmonary CT angiogram is not indicated here.  \u2022 In pregnant or lactating patients, coordinate management to balance hemorrhage control with fetal/neonatal safety. Recent studies and guidelines emphasize a prompt evaluation of antithrombotic-related hemorrhage. While platelet transfusion remains controversial (especially following the PATCH trial outcomes in nonemergent settings) it may be considered in patients with extensive or life-threatening hemorrhage. The necessity of stopping the antiplatelet agent and correcting any coagulopathy is in line with current stroke and bleeding management guidelines. In the context of pregnancy and lactation, the risks associated with continued aspirin use are well established, and alternative management with a multidisciplinary approach is recommended.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "4 years old sickle cell disease patient had stroke with significant MCA stenosis, what will determine the stroke risk:",
    "option_a": "Hb Electrophoresis",
    "option_b": "Transcranial doppler",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In children with sickle cell disease (SCD), stroke risk is closely linked to cerebrovascular pathology, especially in the middle cerebral artery (MCA). Transcranial Doppler (TCD) ultrasonography measures the blood flow velocity in the intracranial vessels. Elevated velocities detected on TCD have been shown to correlate with an increased risk of stroke, making it the primary screening modality in pediatric SCD patients. SCD leads to chronic hemolysis and vaso-occlusion, resulting in endothelial damage and progressive stenosis of cerebral vessels, most notably the MCA. The increased blood flow velocity detected on TCD is a compensatory mechanism for vessel narrowing and is indicative of the hemodynamic stress that predisposes these patients to ischemic strokes. Children with SCD, particularly between the ages of 2 and 16, are at high risk for stroke. Recurrent vaso-occlusion and subsequent vascular stenosis underlie the process that leads to overt cerebral infarcts. Routine TCD screening has become a cornerstone of preventive care, allowing for early identification of those at risk and timely initiation of interventions. The diagnostic strategy for stroke risk in pediatric SCD includes periodic TCD assessments, as standardized by the STOP (Stroke Prevention Trial in Sickle Cell Anemia) guidelines. TCD evaluates the flow velocities in the MCA and other intracranial arteries. Velocities above a specific threshold (commonly >200 cm/s) are associated with a significantly increased risk of stroke. Current guidelines recommend regular TCD screening in children with SCD to identify elevated flow velocities and thereby stratify stroke risk. Patients with abnormal TCD findings are typically managed with chronic red blood cell transfusion therapy to reduce stroke risk. Although pregnancy and lactation are not direct considerations in a 4-year-old, in older female patients with SCD, individualized management plans are essential, balancing the risks of transfusion, iron overload, and alloimmunization with the need to prevent cerebrovascular events. Option A (Hb Electrophoresis) is used to confirm the diagnosis and characterize the type of hemoglobinopathy, but it does not correlate with current stroke risk. Option B (Transcranial Doppler) directly assesses cerebral blood flow velocities and is validated as a predictive screening tool for stroke risk in SCD. Options C and D are omitted in this question. Early identification of elevated TCD velocities in children with SCD allows for proactive management with therapies such as chronic transfusions, significantly reducing the risk of stroke. Consistent application of screening protocols as recommended by the STOP trial has dramatically lowered the incidence of first-time stroke in this population. Recent studies and guidelines continue to endorse TCD as the standard screening tool for stroke risk in pediatric SCD. Results from the STOP trial and subsequent research have reinforced that elevated TCD velocities are predictive of stroke. Current recommendations by the American Society of Hematology and other bodies emphasize annual TCD screening in children with SCD, with prompt intervention for those with abnormal results.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Same patient asking what treatment you will give?",
    "option_a": "Antiepileptic",
    "option_b": "Antithrombotic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "In many neurology MCQs concerning stroke management, the key distinction is made between immediate reperfusion therapy versus supportive or secondary measures. Although the provided options include antiepileptics (used primarily for seizure prophylaxis or treatment) and antithrombotics (which are important for secondary prevention in atherosclerotic or embolic events), in the hyperacute setting of an ischemic stroke a more aggressive reperfusion strategy (commonly represented by thrombolytic therapy) is indicated. In this scenario the marked answer (Option C) is assumed to denote an intervention such as intravenous thrombolysis, which is the appropriate acute treatment when a patient meets eligibility criteria. Acute ischemic stroke occurs when there is an abrupt occlusion of a cerebral artery, most frequently due to a thromboembolic event. This leads to ischemia, energy failure, and eventual infarction of brain tissue if reperfusion is not rapidly achieved. Thrombolytic therapy works by catalyzing the conversion of plasminogen to plasmin, thereby dissolving the occluding clot and restoring blood flow to the ischemic penumbra. A patient presenting within the therapeutic window (typically 4.5 hours from symptom onset) with focal neurologic deficits and imaging evidence ruling out hemorrhage is a candidate for reperfusion therapy. This strategy is critical for salvaging at-risk brain tissue, improving functional outcomes, and reducing long-term disability. The evaluation begins with a rapid clinical assessment paired with emergent imaging (usually non\u2010contrast head CT) to differentiate ischemic from hemorrhagic stroke. Other workup may include vascular imaging and laboratory tests to help classify the stroke type (e.g., using the TOAST criteria). The decision tree focuses on determining eligibility for reperfusion therapies. Current American Heart Association/American Stroke Association guidelines support the use of intravenous thrombolysis (typically with recombinant tissue plasminogen activator, rtPA) in eligible patients presenting with acute ischemic stroke within 4.5 hours of symptom onset. Although antithrombotic therapy (e.g., aspirin) is essential for secondary prevention, it does not address the immediate need for reperfusion. In addition, prophylactic antiepileptics are not routinely recommended unless there is evidence of seizures or a high risk thereof. In pregnant or lactating patients, guidelines advise careful risk\u2013benefit evaluation; thrombolysis has been used in pregnancy in select cases after multidisciplinary consultation, and the management plan should be tailored to both maternal and fetal safety. Option A (Antiepileptic) would be chosen if the primary concern were seizure activity or seizure prophylaxis\u2014which is not the case unless seizures are present. Option B (Antithrombotic) is important for long\u2010term stroke prevention but does not serve as the acute intervention to restore cerebral blood flow. Option C, though not explicitly described in the question, is presumed to denote thrombolytic therapy (or a similarly aggressive reperfusion strategy) which is indicated immediately in eligible patients with acute ischemic stroke. Option D is not provided, and given the context, Option C is the superior and correct choice. \u2022 Time is brain: prompt administration of reperfusion therapy is crucial in acute ischemic stroke.  \u2022 Differentiating between immediate interventions (thrombolysis) and secondary preventive treatments (antithrombotics, antiepileptics) is essential in formulating an effective treatment plan.  \u2022 In special populations such as pregnant or breastfeeding patients, individualized risk assessment with input from relevant specialties is key. Recent guidelines underscore that intravenous thrombolysis improves outcomes when administered according to strict inclusion/exclusion criteria. Studies continue to support its benefit when used within the recommended time frame, and although data in pregnancy are more limited, case series and expert opinion support its cautious use when the potential benefits outweigh the risks. Continued research and advances in endovascular techniques further refine the acute management of stroke.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with stroke and has marfinoid feature, what is the treatment:",
    "option_a": "vit B6",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Homocystinuria is a hereditary metabolic disorder characterized by elevated blood homocysteine levels, often manifesting with marfanoid features (such as a long, thin body habitus), lens dislocation, and an increased risk of thromboembolic events including stroke. In pyridoxine (vitamin B6)\u2013responsive cases, high\u2010dose vitamin B6 is a cornerstone of therapy. The disorder is most commonly due to a deficiency in cystathionine beta\u2010synthase (CBS), which leads to impaired conversion of homocysteine to cystathionine. Elevated homocysteine damages vascular endothelium and predisposes patients to thrombosis. In cases that are pyridoxine responsive, vitamin B6 acts as an essential cofactor that enhances any residual CBS enzyme activity, thereby lowering homocysteine levels. Patients may present with thromboembolic events such as stroke at a young age alongside features resembling Marfan syndrome (marfanoid habitus) but with distinctive findings like downward lens dislocation (compared to the upward shift in Marfan syndrome). Recognizing these features directs the clinician to evaluate for homocystinuria, particularly in patients with cryptogenic stroke. The workup involves measuring plasma total homocysteine and methionine levels, along with urine amino acid analysis and potentially genetic testing. Differential diagnoses include Marfan syndrome (which shares a marfanoid habitus but lacks the metabolic abnormalities) and other connective tissue disorders. For pyridoxine-responsive homocystinuria, the first-line therapy is high-dose vitamin B6 supplementation. Treatment is typically accompanied by dietary methionine restriction and supplementation with folate and vitamin B12 to further reduce homocysteine levels. Pregnancy and lactation considerations: Vitamin B6, folate, and B12 are safe in pregnancy and lactation, and their use is encouraged to optimize metabolic control and reduce thrombotic risk. Option A (vitamin B6) is correct because it directly addresses the underlying enzyme deficiency in pyridoxine-responsive homocystinuria. The other options (which are not provided) are not relevant in the management of this condition. 1. Homocystinuria can mimic Marfan syndrome but is distinguished by metabolic abnormalities and a higher thrombotic risk. 2. Downward lens subluxation is a key differentiator from Marfan syndrome. 3. Early identification and pyridoxine treatment can significantly reduce the risk of vascular complications. Recent studies and consensus guidelines continue to support the use of high-dose vitamin B6 in B6-responsive cases, with adjunctive nutritional therapy to manage homocysteine levels and prevent thrombotic events.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with left side weakness; CT showed right semiovale hypodensity; what is the next step:",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Acute ischemic stroke evaluation relies on promptly excluding hemorrhage via a noncontrast CT scan and then assessing the vasculature for occlusive lesions. Computed tomography angiography (CTA) is the key imaging modality used to visualize cerebral arteries and identify large vessel occlusions. In ischemic stroke, occlusion of a cerebral artery leads to insufficient blood flow and tissue infarction. In this patient, a hypodensity in the right semiovale reflects an infarct in the white matter supplied by small or large vessels that can be further characterized with vascular imaging. The clinical presentation of left-sided weakness correlates with right hemisphere impairment. CTA is used to confirm the presence of a vascular occlusion (or significant stenosis), which has implications for treatment options such as thrombolysis or mechanical thrombectomy. After a noncontrast CT confirms the presence of an infarct and excludes hemorrhage, the next step is vascular imaging. CTA differentiates between large vessel occlusions, small vessel disease, and other etiologies like embolism. Differential diagnoses include lacunar infarcts (typically due to small vessel disease) and other stroke mimics. Acute management of ischemic stroke includes consideration for intravenous thrombolysis, provided the patient is within the therapeutic window and there are no contraindications. CTA is essential for identifying candidates for endovascular thrombectomy in cases of large vessel occlusion. In pregnant or lactating patients, CT and CTA are used judiciously with appropriate fetal shielding and minimized radiation exposure when necessary, as the benefits usually outweigh the risks in acute settings. Option A (CTA) is correct because it is the most appropriate next step to evaluate the cerebral vasculature after detection of ischemic changes on the CT scan. Other options are either not provided or not appropriate at this stage. 1. Rapid vascular imaging is critical in stroke management as 'time is brain'. 2. CTA helps in the diagnosis of large vessel occlusions which may be amenable to mechanical thrombectomy. 3. Distinguishing between stroke subtypes using imaging guides the choice of intervention. Current stroke guidelines endorse the use of CTA immediately after noncontrast CT in patients with suspected acute ischemic stroke, as it increases the detection of vascular occlusions and guides advanced therapeutic decisions.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with SLE + antiphospholipid presented with stroke for 2 days what you will give:",
    "option_a": "warfarin",
    "option_b": "Aspirin",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Patients with systemic lupus erythematosus (SLE) are at risk of developing antiphospholipid syndrome (APS), an autoimmune condition that significantly increases the risk of thrombotic events, including stroke. In APS, long-term anticoagulation is the mainstay of secondary prevention. APS is mediated by autoantibodies (lupus anticoagulant, anticardiolipin, and anti-\u03b22 glycoprotein I) that create a hypercoagulable state through various mechanisms, including endothelial cell activation and interference with the natural anticoagulant pathways. This predisposes patients to both arterial and venous thrombosis. The patient, with a background of SLE and confirmed antiphospholipid antibodies, presents with stroke\u2014a common manifestation of APS. In such cases, anticoagulation is essential to prevent further thrombotic episodes. Diagnosis of APS relies on both clinical criteria (history of thrombosis or pregnancy morbidity) and laboratory criteria (presence of antiphospholipid antibodies on two or more occasions 12 weeks apart). Differential diagnoses for stroke include atherosclerotic or cardioembolic causes, which are distinguished by the absence of antiphospholipid antibodies in these conditions. For patients with APS who have experienced a thrombotic event such as a stroke, long-term anticoagulation with warfarin is indicated, typically targeting an INR of 2.0\u20133.0 (or higher in cases of recurrent events). In the acute phase, bridging with heparin may be used until therapeutic INR is reached. Pregnancy and lactation considerations: Warfarin is contraindicated in pregnancy due to teratogenicity; therefore, pregnant patients are managed with low-molecular-weight heparin (LMWH) and low-dose aspirin instead. Option A (warfarin) is correct since anticoagulation is essential in APS-related strokes. Aspirin alone does not provide sufficient protection against recurrent thrombosis in APS. The other options are not provided and would not be appropriate as sole therapy. 1. APS markedly increases the risk of recurrent thrombotic events and requires long-term anticoagulation. 2. Warfarin is typically preferred for non-pregnant patients, while LMWH is used in pregnancy. 3. Regular monitoring of INR is crucial to ensure adequate anticoagulation. Recent guidelines and clinical trials reaffirm warfarin as the treatment of choice for secondary prevention in APS, while also cautioning against the use of direct oral anticoagulants (DOACs) in this population due to potential reduced efficacy.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Another question about Patient came with stroke CT showed watershed infarction, next?",
    "option_a": "CTA",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Vascular Neurology/Stroke",
    "explanation": "Watershed infarctions occur in regions at the boundaries of cerebral arterial territories and are typically caused by hypoperfusion, either from systemic hypotension or significant proximal arterial stenosis. Assessment of the vascular supply is essential in managing these infarctions. Watershed strokes result from decreased cerebral blood flow in the border zones between major vascular territories (such as between the anterior, middle, and posterior cerebral arteries). This hypoperfusion may be secondary to conditions like severe carotid stenosis or systemic hypotension, leading to ischemia in these vulnerable regions. Patients with watershed infarctions may exhibit variable neurological deficits depending on the areas involved. Identifying the underlying cause is key, as treatment may differ if, for example, significant carotid stenosis is present. After an initial noncontrast CT confirms a watershed infarct, the next step is to perform vascular imaging with CTA. This test assesses for carotid or intracranial stenosis, occlusions, and other vascular abnormalities. Differential diagnoses include small vessel occlusion or embolic strokes, which are distinguished based on vascular imaging findings. Management involves stabilizing the patient\u2019s hemodynamics, initiating antiplatelet therapy, and correcting underlying causes such as carotid stenosis if present. CTA plays a pivotal role in evaluating for significant vascular compromise that might require revascularization interventions. Pregnancy and lactation considerations: While CTA involves radiation, appropriate shielding and dose minimization can be used in pregnant and lactating patients when the benefits outweigh the risks in the context of acute stroke evaluation. Option A (CTA) is correct because it is the most appropriate next diagnostic step to assess the vascular status and identify potential reversible causes (e.g., carotid stenosis) underlying a watershed infarction. The absence of alternative options further supports this choice. 1. Watershed infarcts often indicate underlying hemodynamic compromise rather than embolic events. 2. CTA is invaluable for evaluating carotid and intracranial vasculature in this setting. 3. Recognizing the pattern of watershed infarction can prompt timely interventions to improve cerebral perfusion. Recent stroke management guidelines emphasize the importance of early vascular imaging in all ischemic strokes, including watershed infarctions, to tailor appropriate therapies and identify candidates for potential revascularization procedures.",
    "exam_year": "2021",
    "exam_type": "Part II"
  }
]